Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-04-14 | Dr. Jeffrey Alan GravesPresident, CEO & Director | -30,50k | 60,39k | Sale to Issuer | 1,98 | 1,43M | -2,09% |
| 2026-04-14 | Ms. Phyllis B. NordstromExec. VP, CFO & Chief Administrative Officer | -1,63k | 3,22k | Sale to Issuer | 1,98 | 793,27k | -0,20% |
| 2026-04-14 | Mr. Reji PuthenveetilExec. VP of Additive Solutions & Chief Commercial Officer | -11,70k | 23,17k | Sale to Issuer | 1,98 | 502,13k | -2,28% |
| 2026-04-14 | Dr. Joseph ZuikerExec. VP of Engineering & Operations | -5,33k | 10,55k | Sale to Issuer | 1,98 | 278,05k | -1,88% |
| 2026-04-14 | Dr. Charles W. HullCo-Founder, Exec. VP, CTO of Regenerative Medicine & Director Emeritus | -4,10k | 8,12k | Sale to Issuer | 1,98 | 518,52k | -0,78% |
| 2026-04-01 | Dr. Charles W. HullCo-Founder, Exec. VP, CTO of Regenerative Medicine & Director Emeritus | -4,46k | 8,34k | Sale to Issuer | 1,87 | 522,62k | -0,85% |
| 2026-04-01 | Mr. Reji PuthenveetilExec. VP of Additive Solutions & Chief Commercial Officer | -17,70k | 33,10k | Sale to Issuer | 1,87 | 513,83k | -3,33% |
| 2026-04-01 | Dr. Joseph ZuikerExec. VP of Engineering & Operations | -8,32k | 15,56k | Sale to Issuer | 1,87 | 283,38k | -2,85% |
| 2026-04-01 | Ms. Phyllis B. NordstromExec. VP, CFO & Chief Administrative Officer | -14,52k | 27,15k | Sale to Issuer | 1,87 | 794,89k | -1,79% |
| 2026-04-01 | Dr. Jeffrey Alan GravesPresident, CEO & Director | -39,95k | 74,71k | Sale to Issuer | 1,87 | 1,46M | -2,66% |
| 2026-04-01 | Mr. Andrew William-Banasick WrightSenior VP of General Counsel & Corporate Secretary | -3,86k | 7,22k | Sale to Issuer | 1,87 | 142,78k | -2,63% |
| 2025-12-12 | Dr. Joseph ZuikerExec. VP of Engineering & Operations | -5,21k | 9,90k | Sale to Issuer | 1,90 | 199,20k | -2,55% |
| 2025-12-02 | Ms. Phyllis B. NordstromExec. VP, CFO & Chief Administrative Officer | -1,73k | 3,53k | Sale to Issuer | 2,04 | 634,41k | -0,27% |
| 2025-09-05 | Dr. Charles W. HullCo-Founder, Exec. VP, CTO of Regenerative Medicine & Director Emeritus | -4,93k | 10,45k | Sale to Issuer | 2,12 | 477,08k | -1,02% |
| 2025-09-05 | Mr. Andrew William-Banasick WrightSenior VP of General Counsel & Corporate Secretary | -5,86k | 12,41k | Sale to Issuer | 2,12 | - | - |
| 2025-09-05 | Dr. Joseph ZuikerExec. VP of Engineering & Operations | -6,73k | 14,27k | Sale to Issuer | 2,12 | 204,41k | -3,19% |
| 2025-09-05 | Ms. Phyllis B. NordstromExec. VP, CFO & Chief Administrative Officer | -13,39k | 28,38k | Sale to Issuer | 2,12 | 636,14k | -2,06% |
| 2025-09-05 | Mr. Reji PuthenveetilExec. VP of Additive Solutions & Chief Commercial Officer | -16,05k | 34,03k | Sale to Issuer | 2,12 | 431,53k | -3,59% |
| 2025-09-05 | Dr. Jeffrey Alan GravesPresident, CEO & Director | -40,13k | 85,07k | Sale to Issuer | 2,12 | 1,25M | -3,11% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
